Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Andrew Meds vs Hims & Hers

Andrew Meds
Graded #177

Lower grade

vs+8.5
Hims & Hers
Graded #55

Higher grade

The verdict

Hims & Hers takes it — 75.6/100 to 67.1/100.

Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHims & Hers +28
54
82
Dose & formulationHims & Hers +14
64
78
Clinical oversightAndrew Meds +26
81
55
Labs & monitoringHims & Hers +27
53
80
FulfillmentAndrew Meds +10
94
84
Contract termsHims & Hers +13
67
80
Andrew Meds · left barHims & Hers · right bar

The numbers

MetricAndrew MedsHims & Hers
WeighScore67.1/10075.6/100
GradeCC
Scorecard rank#177#55
Semaglutide$199/mo (product page; two live intake funnels price semaglutide differently)$199/mo
Tirzepatide$299/mo (product page; neither GLP-1 funnel offered tirzepatide when walked)Not disclosed
CoverageAll 50 states plus Washington, D.C.All 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Andrew Meds

Graded #177 · C

Strengths

  • States its compounding class in plain language on the product pages — a 503(A) pharmacy or a 503(B) outsourcing facility — which most of the field leaves unstated
  • Names the prescribing practice in the footer of every page
  • Prices sit on the product pages before any intake, and free expedited shipping is stated rather than added at checkout
  • Serves all 50 states and the District of Columbia, stated in the footer without a hedge

Where it loses points

  • Three live semaglutide figures the site never reconciles: $199 a month on the product page, $99 a month in the microdosing funnel, and $149 for a four-week supply in the second funnel
  • Every Get Started button on the compounded semaglutide page lands on a microdosing intake, which is a different program from the one the page describes
  • Both GLP-1 intakes ended offering only semaglutide, so whether tirzepatide can be bought through the current funnels is unclear
  • The funnel promises a 100% success guarantee and a money-back weight-loss guarantee while the Terms say refunds are not offered for partially used subscription periods
  • The pharmacy class is stated but no pharmacy is named, and no individual clinician or NPI appears anywhere
  • An oral tirzepatide product is advertised on both GLP-1 pages and every link to it resolves to a page that does not list it
Hims & Hers

Graded #55 · C

FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.

Strengths

  • Nationwide
  • Polished app
  • Strong brand trust

Where it loses points

  • Tirzepatide pricing inconsistently disclosed
  • Industry-wide compounding scrutiny

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 536 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard